- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings, Neonc Technologies Holdings, Medicus Pharma, YY Group Holding, and Vivos Therapeutics | 564 | ACCESS Newswire | The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution... ► Artikel lesen | |
| Di | NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 10.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | NeOnc Technologies Holdings GAAP EPS of -$3.20 | 2 | Seeking Alpha | ||
| 01.04. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q4 2025 Financial Results | 115 | GlobeNewswire (Europe) | CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 31.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 23.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.03. | NeOnc Technologies appoints David Choi as chief accounting officer | 1 | Investing.com | ||
| 13.03. | David Choi wird neuer Chief Accounting Officer bei NeOnc Technologies | 1 | Investing.com Deutsch | ||
| 13.03. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints David Choi as Chief Accounting Officer | 1.297 | GlobeNewswire (Europe) | CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 12.03. | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) | 226 | Newsfile | Dallas, Texas--(Newsfile Corp. - March 12, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).... ► Artikel lesen | |
| 06.03. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 04.03. | NeOnc sets Phase 2 dose for brain cancer drug NEO212 | 2 | Investing.com | ||
| 27.02. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | NeOnc Technologies to present Phase 1 trial data on March 4 | 1 | Investing.com | ||
| 06.02. | NEONC TECHNOLOGIES HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 30.01. | NeOnc Technologies raises $16 million in private placement | 5 | Investing.com | ||
| 30.01. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management | 1 | GlobeNewswire (USA) | ||
| 29.01. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,40 | -4,14 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| KYMERA THERAPEUTICS | 86,93 | -0,82 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| QIAGEN | 34,950 | -0,14 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| DISC MEDICINE | 71,41 | -0,45 % | Disc Medicine Inc: Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,610 | -1,58 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 16,580 | -1,31 % | Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | ||
| BIONTECH | 89,05 | +1,83 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| ERASCA | 21,700 | +14,24 % | Jefferies reiterates Erasca stock Buy rating ahead of ASCO data | ||
| ENVERIC BIOSCIENCES | 3,575 | +96,97 % | Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? | ||
| PSYENCE BIOMEDICAL | 11,210 | +47,69 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,410 | -3,44 % | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market | ||
| HARMONY BIOSCIENCES | 29,530 | -1,47 % | Dravet-Syndrom: Harmony Biosciences präsentiert neue Studiendaten | ||
| EVOTEC | 5,440 | -2,33 % | Aktie "falsch bewertet": Wie Evotec am KI-Boom verdient | KI macht Arzneimittelforschung billiger - und schafft paradoxerweise mehr Arbeit für Evotec. Warum Berenberg die Aktie trotz operativer Schwäche klar zum Kauf empfiehlt. Die Pharmaindustrie setzt zunehmend... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 31,390 | +6,08 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,120 | -0,08 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data |
Das Unternehmen NEONC TECHNOLOGIES HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,180 Euro und damit -3,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.